The polyunsaturated fatty acids (PUFAs) arachidonic acid (AA) and linoleic acid (LA) and the enzymes that metabolize these PUFAs have emerged to be essential regulators of crucial cellular processes in the context of cancer and inflammation. AA is a 20-carbon fatty acid that is released from phospholipids of the nuclear membrane with the activity of phospholipase A2 (PLA 2 ), which is further metabolized by cyclooxygenases (COXs) or lipoxygenases (LOXs).
of 15-LOX-1 and discuss the newly described roles of 15-LOX-1 and its related pathways in the context of inflammation and cancer, with particular emphasis on the tumour microenvironment (TME).
| ENZ YMATI C AC TIVIT Y OF 15-LOX-1
In addition to free fatty acids such as AA and LA, 15-LOX-1 can oxygenate a broad range of substrates that include esterified forms of naturally occurring polyenoic fatty acids, even when they are bound to biomembranes or lipoproteins. 12 The enzyme has been shown to bind to biomembranes through its N-terminal domain 12 and is therefore thought to be in close proximity for direct oxygenation of complex lipids. Alternatively, it may oxygenate free fatty acids; the products, namely 15-HETE and 13-HODE, are more polar and may be incorporated into the membrane phospholipids. 13 Additionally, 15-LOX-1 metabolites have been shown to activate NADPH oxidases leading to the production of reactive oxygen species (ROS), 14 which in turn may also oxygenate membrane lipids. It is therefore plausible that 15-LOX-1 itself, or its oxygenation products may cause alterations in the structure of biomembranes and thereby alterations in cellular functions.
| REG UL ATI ON OF 15-LOX-1 E XPRE SS I ON
Regulation of ALOX15 expression is complex and involves multiple mechanisms including transcriptional and epigenetic regulation.
| Transcriptional regulation
The expression of 15-LOX-1 in various cell types (both epithelial and stromal) was shown to be up-regulated when the cells were treated with the anti-inflammatory T-helper subset 2 (TH-2) cytokines IL-4 or IL-13. 15, 16 An up-regulation of 15-LOX-1 expression was also observed during differentiation of CD34 + hematopoietic progenitor cells to dendritic cells in the presence IL-4 and GM-CSF. 17 In human macrophages, which appear to constitutively express 15-LOX-1 at low levels, IL-13 induced 15-LOX-1 mRNA and protein synthesis leading to enhanced production of 15-HETE. 18 Stimulation of 15-LOX-1 expression by IL-4 and IL-13 involves the transcription factor STAT-6 15 ( Figure 2A ). In human monocytes, induction of JAK2 and TYK2 tyrosine kinases by IL-13 induced 15-LOX expression, through STAT-6 dimerization and nuclear import. 19 However, IFN-γ, a product of TH-1 lymphocytes, was observed to inhibit ALOX15 gene expression induced by IL-13 in monocytes. 20 IL-4 mediated induction of 15-LOX-1 in A549 cells 21, 22 was shown to be through the up-regulation of the histone acetyltransferase activity of the Creb-binding protein/p300 (CBP/p300), which can acetylate both nuclear histones and STAT-6 in lung carcinoma cells ( Figure 2B ). In the same study it was suggested that IL-4 stimulation caused STAT-6 phosphorylation; and ALOX15 expression was enhanced provided the relevant histones were acetylated and the STAT-6 binding sites became unmasked. 23 Ku autoantigen (DNA helicase) was also shown to induce 15-LOX-1 gene expression in A549 cells after treatment with IL-4 and IL-13. 24 Additionally, STAT-1 and STAT-3 phosphorylation through p38
MAPK activation was shown to be important for 15-LOX-1 expression in human primary monocytes after IL-13 treatment. erating a novel SPI1 transcription factor binding site. 26 On the other hand, GATA-6 was shown to contribute to transcriptional suppression of 15-LOX-1 probably by preventing the binding of activator proteins. GATA-6 expression was reported to be higher in transformed colon epithelial cells than the normal epithelia. 27 Shureiqi et al have shown that in colon cancer cell lines, GATA-6 knockdown was insufficient by itself but contributed significantly to restoring 15-LOX-1 expression. 
| Epigenetic regulation
Chromatin structure can influence gene transcription, through post- and HC toxin, were also shown to induce 15-LOX-1 transcription and protein expression in colon cancer cells. [30] [31] [32] In line with this, the nucleosome remodelling and deacetylase (NuRD) complex, consisting of core proteins HDAC1, HDAC2, Mi2, MTA1/2/3 and others, was
shown to suppress 15-LOX-1 expression in CRC. 33 HDACi can inhibit the core HDAC components of this complex, which in turn may contribute to the re-activation of 15-LOX-1 transcription 33 ( Figure 2C ). Caco-2 with 13-HODE resulted in decreased cell proliferation. 46 In the same study, it was shown that in adenoma tissues 15-LOX-1 expression was spread throughout the sample with a lower intensity of staining in the neoplastic epithelium and a higher intensity of staining in the inflammatory areas while in normal controls the expression was mostly restricted to the colonic mucosal epithelium. 46 Based on this finding, it might be possible to argue that 15-LOX-1 expression must be maintained at a high concentration in a confined area for its biological effects, and that in the case of properties of 15-LOX-1. 47 Treatment of RKO and HT-29 cells with sulindac and NS-39 led to increased 15-LOX-1 expression and subsequent 13-HODE production, cell growth inhibition and increased apoptosis. 48 In the same study, the effects of the NSAID treatments became unobservable when 15-LOX-1 was inhibited with caffeic acid. 48 In addition, exogenous addition of 13-HODE to these cells led to growth inhibition and apoptosis. 48 Treatment with celecoxib, another NSAID that selectively inhibits COX-2, resulted in increased 15-LOX-1 expression and induction of apoptosis, suggesting a therapeutic role of celecoxib in CRC. 44 Interestingly, a negative correlation between the expression and activity of 15-LOX-1 and COX-2 has been reported in colonic neoplasia indicating an alteration in the species of bioactive lipids being produced in the malignant tissues from the pro-apoptoic molecules to the more mitogenic prostaglandins. 
| 15-LOX-1 IN C ARCINOG ENE S IS

| ROLE OF 15-LOX-1 IN INFL AMMATI ON
Inflammation is the sum of biological processes such as swelling, redness, pain and heat. While essential during pathogenic infections, acute inflammation should be resolved when the infection is cleared out through the process of resolution. A highly regulated spatial and temporal class switching of eicosanoids occurs in inflamed tissues, starting with the production of pro-inflammatory mediators through the COX and LOX pathways followed by the production of resolution mediators such as resolvins and lipoxins. 59, 60 However, overproduction of the pro-inflammatory mediators and a deficiency of resolution may lead to chronic low grade inflammation and associated diseases such as cancer. 61 Expression of human 15-LOX-1 resulted in a significant inhibition of the activity of NF-κB, along with lower levels of tumour necrosis factor-α (TNF-α) and its target inducible nitric oxide synthase (iNOS). 62 Mechanistically, our group has shown that the inhibition of NF-κB activity was through the phosphorylation and activation of PPAR-γ by its ligand 13-HODE in 15-LOX-1 overexpressing CRC cell lines. 38 In a colitis-associated colon cancer (CAC) model, 15-LOX-1 inhibited IL-6/STAT-3 signalling and tumourigenesis by down-regulating PPAR-δ. 63 Similarly, in a trinitrobenzenesulfonic acid-induced IBD mouse model, the administration of milk fermented by a Lactococcus lactis strain producing 15-LOX-1 alleviated symptoms of colitis. 64 These data collectively illustrate that chronic inflammation, a cornerstone of colon cancer may be ameliorated by the expression and activity of 15-LOX-1.
Inflammatory resolution is an active process aimed to prevent the progression from acute-resolving to persistent-chronic inflammation to inhibit further tissue damage. 65 Resolvins, protectins, lipoxins and maresins are endogenous lipid mediators that are synthesized during the resolution phase of acute inflammation. to displace Raf-1 and activate MAPK/ERK pro-inflammatory signalling pathway, and induce MUC5AC expression. 84 In another study, after IL-13 treatment, binding of 15-LOX-1 with PEBP1 was shown to contribute the desensitization of β2-Adrenergic receptor (β2AR) through release of G protein receptor kinase 2 (GRK2), which may lead to loss of therapeutic effects in patients with airway diseases. 82 Therefore, 15-LOX-1 and PEBP1 interaction has been suggested as a potential target in patients with airway diseases, such as asthma, for restoring β2AR sensitization to enhance adenylate cyclase activity and cAMP synthesis, which can promote smooth muscle relaxation in airways and blood vessels as well as enhance ciliary beating and mucin clearance. 82 More recently, in silico analysis of the interaction between 15-LOX-1 and PEBP1 in humans was predicted to modify the 15-LOX-1 protein in a way that would allow the enzyme to efficiently oxygenate esterified PUFAs. In human airway epithelial cells, PEBP1 and 15-LOX-1 were shown to co-localize and enhance the formation of oxidized lipid species, which, in the absence of an efficient antioxidant system (such as GPX4) could trigger cell death via ferroptosis. 85 In a diabetic retinopathy model, a hyperglycaemiainduced reduction in 15-LOX-1 levels and downstream production of resolvin D1 (RvD1) was reported, while activation of β2AR signalling pathway rescued these decreases in 15-LOX-1 and RvD1. 86 Therefore, the biological action of 15-LOX-1 in inflammation can be different in airway epithelial cells when compared to retinal cells. It should be also noted that several mediators that elevate the inflammatory phase of inflammation can simultaneously initiate an active resolution program, which can be specific to associated pathologies, 65 with context specific molecular interactions and signalling networks.
Atherosclerosis is accepted as an inflammatory disease involving the vascular wall. 87 LOXs are involved in the pathogenesis of atherosclerosis as reviewed previously. 88 
| Modulation of cellular motility in the microenvironment
Metastasis is a complex process that requires cancer cells to undergo epithelial to mesenchymal transformation, detach from the resident tumour, migrate through the blood vessels to a secondary tumour site where the cells extravasate into the tissue where the cells undergo transformation to a more epithelial phenotype and promote the secondary tumour formation. 110 The TME, particularly the composition of ECM, is a significant determinant of whether a tumour can successfully metastasize to distant organs. 111 Recent data indicate that 15-LOX-1 may have an antimetastatic role, although the detailed mechanisms and specific interactions with the TME need to be elucidated.
We have shown that 15-LOX-1 re-expression in the colon cancer cell lines HCT-116 and HT-29 can enhance adhesion of cells to fibronectin, reduce cellular motility, wound healing, migration and invasion in vitro 7 through the reduced expression of MTA-1 (Metastasis-associated protein 1), a master regulator of metastasis in many tumours including CRC. 112, 113 Functionally, the reduced motility seen in CRC cell lines overexpressing 15-LOX-1 was rescued when MTA-1 was overexpressed. 113 Other studies have indicated that the mechanism behind reduced motility in CRC cell lines expressing 15-LOX-1 could also be attributed to a loss of VEGF expression and secretion. 114 Data on the role of 15-LOX-1 expression of the TME in metastatic spread is relatively limited. Activation of PPAR-γ by 13-HODE was shown to inhibit metastasis to the peritoneal cavity in an in vivo mouse gastrointestinal peritoneal metastasis model and reduced motility in human colon and gastric cancer cell lines. 115 A transgenic mouse model that over-expressed 15-LOX-1 in endothelial cells under the control of the murine preproendothelin-1 promoter showed reduced tumour metastasis in both mammary and Lewis lung cancer models. 116 The same study also reported decreased expression of EGF and increased expression of apoptosis marker Bax indicating an overall tumour suppressive effect. 116 Future studies are necessary to tease out the delicate balance between different 15-LOX-1 derived bioactive lipids in the TME and their role in epithelial-stromal cell interactions.
| Modulation of vasculature in the microenvironment
The vasculature plays a crucial role in determining the composition of the TME. Tumour associated vasculature is usually chaotic and generally unable to meet the requirements of the growing tumour, generating pockets of hypoxia. 109 These angiogenic cues result in the expression of growth factors such as VEGF that stimulate the sprouting of new blood vessels in a haphazard and disorderly manner. Moreover, these blood vessels are often leaky with uneven blood flow and are unable to carry nutrients or drugs efficiently to the TME. The same cells also showed enhanced expression of the cell adhesion F I G U R E 4 Implications of 15-LOX-1 in angiogenesis in different models. 15-LOX-1 has been implicated as a factor that both activates and inhibits angiogenesis. Expression of 15-LOX-1 in ECs reduced angiogenesis by reducing VEGF-A, VEGF-R2 and eNOs mRNA, and NO bioactivity, in vitro. In vivo, down-regulation of VEGFR-2 expression was via the upregulation of PPAR-γ. 13-HODE produced by 15-LOX-1 expressing cancer cells was shown to inhibit angiogenesis through enhanced expression of thrombospondin-1 (TSP-1) and ICAM-1 in ECs.
Increased ICAM-1 expression may increase the recruitment of leukocytes and reduce endothelial cell anergy. On the other hand, 15-HETE was shown as a tumourigenic factor in epithelial cells, and a pro-angiogenic factor in ECs by activating the PI3K pathway. 15-HETE was also found to mediate EC migration, tube formation and angiogenesis through enhanced ATF-2 activity via the mitogen-activated protein kinase (MAPK, Src, Rac1, MEK1, JNK1) cascade. The other PUFA metabolites generated by 15-LOX-1 activity need to be determined in order to clarify the context-dependent action of the enzyme molecule ICAM-1. Endothelial cell-leukocyte interactions are mediated by the expression of CAMs, which may be reduced in tumour associated endothelial cells. 135, 136 A reduction in adhesion proteins such as ICAM-1 can lead to endothelial cell anergy, causing reduced recruitment of immune cells to the TME and thereby immune suppression. 137 Treatment of HUVECs with 13-HODE mimicked most of the anti-angiogenic effects of 15-LOX-1. 133 Therefore, these data suggest that 15-LOX-1 related metabolites have the potential to be used as a therapeutic option to drive antitumour immunity through immune cell infiltration.
| FUTURE PER S PEC TIVE S
To date, the 15-LOX-1 field has attributed both pro-and anti- 
| CON CLUS IONS
There is no doubt that lipids are crucial in signalling and cellular physiology in both health and disease. The importance of lipid metabolizing LOXs in the generation of pro-inflammatory mediators and more recently the pro-resolution mediators have firmly established these enzymes as important players in determining disease outcomes and re-establishing homeostasis.
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